Close Menu

NEW YORK – Cambridge, UK-based cancer startup Biofidelity said on Thursday that it has raised $12 million in a Series A financing round.

The firm will use the funding to accelerate the development and clinical validation of oncology panels for treatment selection and patient monitoring, with an initial focus on non-small cell lung cancer.

The financing round was led by BlueYard Capital, with additional funding from investors including Longwall Ventures and Agilent Technologies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Mar
30
Sponsored by
Menarini Silicon Biosystems

This webinar will provide an overview of the current state of circulating tumor cell (CTC) enumeration for clinical use in metastatic breast cancer.